Intelligence Database
Filter and compare LongevityNext intelligence records by evidence stage, region, and sector.
Life Biosciences sponsors ER-100, an investigational epigenetic-therapy study for optic-nerve conditions. The registered phase 1 trial, NCT07290244, concerns open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. It is an early clinical test of a defined intervention in specific patient groups.
Scores have not been assigned.
Insilico Medicine combines AI-based discovery with therapeutic development. Its rentosertib program targets TNIK in idiopathic pulmonary fibrosis. The listed company, InSilico Medicine Cayman TopCo, and the trial sponsor, InSilico Medicine Hong Kong Limited, have different legal roles.
Scores have not been assigned.
Stealth BioTherapeutics is the applicant named in the original FORZINITY approval. This elamipretide product received US accelerated approval on 19 September 2025 to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. The approved indication is specific to that disease and population.
Scores have not been assigned.
UNITY Biotechnology pursued therapies directed at senescent cells. Its lead retinal program, foselutoclax, also called UBX1325, was designed to inhibit the survival protein BCL-xL. This is a historical company profile: Unity Biotechnology, Inc. filed for dissolution effective 26 September 2025, after ceasing clinical development.
Scores have not been assigned.
BioAge Labs is a public clinical-stage biopharmaceutical company that describes a human-aging-biology platform. This source-reviewed profile treats BioAge as a company-and-pipeline intelligence profile; BGE-102, APJ, and STRIDES context remain company-reported or registry-backed, not clinical outcome proof.